Cancer/Oncology

Jeffery Klco, MD, PhD, St Jude Children's Research Hospital, Memphis, TN, USA

Elizabeth Swisher, MD, University of Washington, Seattle, WA, USA

Stephen Lincoln, Invitae, San Francisco, CA, USA

Eric H. Bernicker, MD, Houston Methodist Hospital, Houston, TX, USA

Valentina Nardi, Massachusetts General Hospital, Boston, MA, USA

Jonathan A. Nowak, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

Angela Jacobson, MS, University of Washington, Seattle, WA, USA

Spliceosome Gene Mutations in MDS
Matthew Walter, MD, Washington University, St. Louis, MO, USA

Inherited Hematopoietic Malignancies
Lucy A. Godley, MD, PhD, The University of Chicago, Chicago, IL, USA

Barbara A. Zehnbauer, PhD, Emory University School of Medicine, Atlanta, GA, USA

Circulating Tumor DNA (ctDNA) Detection in CSF in a Patient with Metastatic Melanoma to the CNS
Andres Moon, MD, University of Washington, Seattle, WA, USA

An Unusual Driver Mutation in a Lung Adenocarcinoma
Erik Nohr, MD, Stanford Healthcare, Palo Alto, CA, USA

LMNA/NTRK1 Fusion in a Paravertebral Soft Tissue Mass
Yulei Shen, MD, PhD, Baylor College of Medicine, Houston, TX, USA

Recurrent Glioblastoma with Primary and Secondary Features in a Patient with a Deficiency of Mismatch Repair
Martin Powers, MD, University of California San Diego, San Diego, CA, USA

Predictor of Response to PARP Inhibitors
Elizabeth M. Swisher, MD, University of Washington, Seattle, WA, USA

Leveraging Personalized Medicine for Diagnosis and Treatment of Pancreatic Cancer
Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, USA

H025 - Ultradeep Error Corrected Next-generation Sequencing (NGS) of ABL1 Kinase Domain Mutations in BCR-ABL1 Positive Malignancies
Nikhil Patkar, MD, Tata Memorial Center, Mumbai, Maharashtra, India

H041 -  Longitudinal Monitoring of AML Tumors with High-throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response
Dennis J. Eastburn, PhD, Mission Bio, Inc., South San Francisco, CA, USA

H014 - Mate Pair Sequencing: Ushering Cytogenetics Into the Era of Personalized Medicine
Nicole Hoppman, PhD, Mayo Clinic, Rochester, MN, USA

H039 - Donor-derived Clonal Hematopoiesis of Indeterminant Potential Mutations are Detected in Transplant Recipients after Allogeneic Hematopoietic Stem Cell Transplant
Jennifer Dunlap, MD, Oregon Health & Science University, Portland, OR, USA

ST002 - Analysis of Urinary Cell-free DNA for Early Detection and Surveillance of Bladder Cancer
Jonathan Dudley, MD, Stanford University, Stanford, CA, USA

ST055 - DNA Sequencing of Human, Epstein-Barr Virus, and Helicobacter Pylori Genomes to Classify and Monitor Gastric Adenocarcinoma
Margaret L. Gulley, MD, University of North Carolina, Chapel Hill, NC, USA

ST107 - Clinical Validation of MSK-ACCESS: An Ultrasensitive Next-generation Sequencing Assay for Liquid Biopsies in the Clinic
A. Rose Brannon, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ST144 - Prognosis Determined by Tumor Mutational Burden (TMB) Using Whole Exome Sequencing (WES)
Evan Fernandez, MS, Weill Cornell Medicine, New York, NY, USA

CRISPR/Cas9 Targeting and Inactivation of Viral DNA Genomes
Bryan R. Cullen, PhD, Duke University Medical Center, Durham, NC, USA

Programmable RNA-targeting CRISPR-Cas Enzymes for RNA Detection and Therapeutics
Mitchell R. O'Connell, PhD, University of Rochester, Rochester, NY, USA

Christina Lockwood, PhD, University of Washington, Seattle, WA, USA

Christopher D. Gocke, MD, Johns Hopkins University, Baltimore, MD, USA

Clinical Applications of Digital PCR
Maria Arcila, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Mark Routbort, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia
Jennifer A. Woyach, MD, The Ohio State University, Columbus, OH, USA

Megan S. Lim, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

Clinical Implications of Mutational Load and Signatures on Replication Repair Deficiency in Cancer
Uri Tabori, MD, PhD, Hospital for Sick Children, Toronto, Ontario, Canada

Hypermutation in Cancer: Burden and Signatures of Mutational Processes
Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA